wiki pageCreated: 2026-04-02T07:18:58By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-therapeutics-nuedexta
📖 Wiki Page
therapeutic887 wordssynced 2026-04-02
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Introduction
Dextromethorphan Quinidine (Nuedexta) For Pseudobulbar Affect is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [^2]
| Property | Value | [@see] |----------|-------| | Drug Name | Dextromethorphan/Quinidine | | Brand Name | Nuedexta | | Drug Class | NMDA Receptor Antagonist / CYP2D6 Inhibitor | | Target | NMDA Receptors, Sigma-1 Receptors | | Route of Administration | Oral | | FDA Approval | 2010 | | Company | Axsome Therapeutics |
</div>
Overview
Nuedexta is a fixed-dose combination of dextromethorphan and quinidine, specifically developed for the treatment of pseudobulbar affect (PBA), also known as emotional lability or pathological laughing and crying. PBA is a neurological condition characterized by involuntary episodes of crying, laughing, or other emotional expressions that are disproportionate or inappropriate to the situation.
Mechanism of Action
Dextromethorphan
[NMDA Receptor](/entities/nmda-receptor) Antagonism: Blocks NMDA receptors in the brain, reducing glutamatergic excitotoxicity
Sigma-1 Receptor Agonism: Modulates calcium signaling and may provide neuroprotective effects
Serotonin/Norepinephrine Effects: Mild reuptake inhibition may contribute to mood stabilization
...
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Introduction
Dextromethorphan Quinidine (Nuedexta) For Pseudobulbar Affect is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [^2]
| Property | Value | [@see] |----------|-------| | Drug Name | Dextromethorphan/Quinidine | | Brand Name | Nuedexta | | Drug Class | NMDA Receptor Antagonist / CYP2D6 Inhibitor | | Target | NMDA Receptors, Sigma-1 Receptors | | Route of Administration | Oral | | FDA Approval | 2010 | | Company | Axsome Therapeutics |
</div>
Overview
Nuedexta is a fixed-dose combination of dextromethorphan and quinidine, specifically developed for the treatment of pseudobulbar affect (PBA), also known as emotional lability or pathological laughing and crying. PBA is a neurological condition characterized by involuntary episodes of crying, laughing, or other emotional expressions that are disproportionate or inappropriate to the situation.
Mechanism of Action
Dextromethorphan
[NMDA Receptor](/entities/nmda-receptor) Antagonism: Blocks NMDA receptors in the brain, reducing glutamatergic excitotoxicity
Sigma-1 Receptor Agonism: Modulates calcium signaling and may provide neuroprotective effects
Serotonin/Norepinephrine Effects: Mild reuptake inhibition may contribute to mood stabilization
Quinidine
CYP2D6 Inhibition: Primarily serves to inhibit CYP2D6, which metabolizes dextromethorphan
Antiarrhythmic Properties: Historically used for cardiac arrhythmias (not relevant to PBA indication)
Combination Rationale
The combination allows dextromethorphan to achieve therapeutic concentrations in the CNS without requiring doses that would cause quinidine-related cardiac effects.
Clinical Applications
Pseudobulbar Affect (PBA)
Indication
Primary PBA: Associated with neurological diseases including:
Amyotrophic lateral sclerosis (ALS)
Multiple sclerosis (MS)
Stroke
Traumatic brain injury
Parkinson's disease
Alzheimer's disease
Efficacy
Primary Endpoint: Reduce the frequency and severity of PBA episodes
Study Results:
Phase 3 trials showed 49% reduction in PBA episode frequency vs placebo
Clinically meaningful improvement in ≥80% of patients
Onset of action within 1-2 weeks
Dosing
Initial Dose: 20/10 mg (dextromethorphan/quinidine) once daily
Evidence: Nuedexta approved based on ALS subgroup data
Multiple Sclerosis
Prevalence: PBA affects ~10% of MS patients
Impact: Social embarrassment, isolation
Evidence: Clinical trials included MS patients
Parkinson's Disease
Prevalence: Less common than in ALS/MS
Consideration: May co-exist with dysarthria
Alzheimer's Disease
Prevalence: Variable, often underdiagnosed
Consideration: May improve caregiver burden
Advantages and Limitations
Advantages
Targeted therapy specifically for PBA
Rapid onset of action (1-2 weeks)
Well-studied in neurodegenerative disease populations
Oral administration
Limitations
Requires twice-daily dosing
Drug interaction concerns
Cost considerations
Not suitable for all patients (cardiac, hepatic issues)
Future Directions
Formulation Development: Once-daily formulations under development
Combination Therapy: Studies evaluating combination with antidepressants
Expanded Indications: Potential for use in other neurological conditions
Biomarker Development: Identifying predictors of response
Background
The study of Dextromethorphan Quinidine (Nuedexta) For Pseudobulbar Affect has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions